Scholarlink

Background <p>Optimized perioperative analgesia is a critical component of Enhanced Recovery After Surgery (ERAS) pathways in robotic-assisted laparoscopic hysterectomy (RALH). In high-volume robotic programs, predictable pain control may influence early mobilization, postoperative stability, and discharge planning. This study evaluated the analgesic efficacy and safety of two low-dose intrathecal morphine (ITM) regimens (0.10&#xa0;mg vs. 0.15&#xa0;mg) in patients undergoing RALH.</p> Methods <p>We conducted a retrospective dual-center cohort study including 100 women who received spinal anesthesia with 0.10–0.15&#xa0;mg of preservative-free intrathecal morphine, with or without levobupivacaine, prior to general anesthesia for RALH. Postoperative pain was assessed using the Visual Analog Scale (VAS) at three time points (PACU arrival, PACU discharge, and 24&#xa0;h postoperatively). Rescue opioid use, hemodynamic events, postoperative nausea and vomiting (PONV), pruritus, and recovery parameters (Alderete Score) were recorded. Comparative analyses were performed between the two ITM dose groups.</p> Results <p>Pain scores remained consistently low across all time points (median VAS = 0; <i>p</i> = 0.302), with rescue analgesia required in 7% of patients (<i>n</i> = 7/100). Compared with the 0.10&#xa0;mg group, the 0.15&#xa0;mg group demonstrated significantly lower pain scores and reduced supplemental opioid requirements. Higher rates of pruritus, PONV, and hypotensive episodes were observed in the 0.10&#xa0;mg group. No cases of respiratory depression or prolonged PACU stay were recorded. Median Alderete Scores were consistently optimal (10/10), indicating stable postoperative recovery.</p> Conclusion <p>Low-dose intrathecal morphine provides effective, opioid-sparing, and motor-preserving analgesia in robotic-assisted laparoscopic hysterectomy. In this cohort, the 0.15&#xa0;mg regimen was associated with improved analgesic balance without an increase in clinically significant adverse events. Within ERAS-based robotic pathways, optimized intrathecal morphine dosing may support predictable recovery and perioperative stability. Observational design precludes causal inference. Prospective randomized studies are warranted to confirm these findings.</p> Trial registration <p>The Ethics Committee approved the study (Protocol ID 3307/2020) on July 6th, 2020, and it was registered in clinicaltrial.gov (NCT07169604).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intrathecal morphine dose optimization in robotic-assisted laparoscopic hysterectomy: a dual-center cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Andrea Russo,
  • Federica Perelli,
  • Paola Aceto,
  • Martina Arcieri,
  • Federica Bernardini,
  • Sara Pregnolato,
  • Rossana Moroni,
  • Teresa Dogareschi,
  • Francesco Meroi,
  • Barbara Costantini,
  • Valerio Gallotta,
  • Francesco Fanfani,
  • Lorenza Driul,
  • Anna Fagotti,
  • Tiziana Bove,
  • Stefano Restaino,
  • Massimo Antonelli,
  • Giuseppe Vizzielli

摘要

Background

Optimized perioperative analgesia is a critical component of Enhanced Recovery After Surgery (ERAS) pathways in robotic-assisted laparoscopic hysterectomy (RALH). In high-volume robotic programs, predictable pain control may influence early mobilization, postoperative stability, and discharge planning. This study evaluated the analgesic efficacy and safety of two low-dose intrathecal morphine (ITM) regimens (0.10 mg vs. 0.15 mg) in patients undergoing RALH.

Methods

We conducted a retrospective dual-center cohort study including 100 women who received spinal anesthesia with 0.10–0.15 mg of preservative-free intrathecal morphine, with or without levobupivacaine, prior to general anesthesia for RALH. Postoperative pain was assessed using the Visual Analog Scale (VAS) at three time points (PACU arrival, PACU discharge, and 24 h postoperatively). Rescue opioid use, hemodynamic events, postoperative nausea and vomiting (PONV), pruritus, and recovery parameters (Alderete Score) were recorded. Comparative analyses were performed between the two ITM dose groups.

Results

Pain scores remained consistently low across all time points (median VAS = 0; p = 0.302), with rescue analgesia required in 7% of patients (n = 7/100). Compared with the 0.10 mg group, the 0.15 mg group demonstrated significantly lower pain scores and reduced supplemental opioid requirements. Higher rates of pruritus, PONV, and hypotensive episodes were observed in the 0.10 mg group. No cases of respiratory depression or prolonged PACU stay were recorded. Median Alderete Scores were consistently optimal (10/10), indicating stable postoperative recovery.

Conclusion

Low-dose intrathecal morphine provides effective, opioid-sparing, and motor-preserving analgesia in robotic-assisted laparoscopic hysterectomy. In this cohort, the 0.15 mg regimen was associated with improved analgesic balance without an increase in clinically significant adverse events. Within ERAS-based robotic pathways, optimized intrathecal morphine dosing may support predictable recovery and perioperative stability. Observational design precludes causal inference. Prospective randomized studies are warranted to confirm these findings.

Trial registration

The Ethics Committee approved the study (Protocol ID 3307/2020) on July 6th, 2020, and it was registered in clinicaltrial.gov (NCT07169604).